Moody Aldrich Partners LLC Sells 47,301 Shares of Verona Pharma PLC American Depositary Share $VRNA

Moody Aldrich Partners LLC reduced its stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 49.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,302 shares of the company’s stock after selling 47,301 shares during the period. Moody Aldrich Partners LLC owned 0.06% of Verona Pharma PLC American Depositary Share worth $4,663,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in VRNA. Frazier Life Sciences Management L.P. lifted its stake in Verona Pharma PLC American Depositary Share by 2.2% in the first quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company’s stock valued at $219,539,000 after buying an additional 73,900 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Verona Pharma PLC American Depositary Share by 1.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company’s stock worth $118,491,000 after buying an additional 32,748 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Verona Pharma PLC American Depositary Share by 381.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company’s stock valued at $103,552,000 after acquiring an additional 1,292,575 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Verona Pharma PLC American Depositary Share by 274.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock valued at $66,119,000 after acquiring an additional 763,353 shares during the last quarter. Finally, Duquesne Family Office LLC raised its position in shares of Verona Pharma PLC American Depositary Share by 12.9% in the 1st quarter. Duquesne Family Office LLC now owns 1,002,080 shares of the company’s stock valued at $63,622,000 after acquiring an additional 114,500 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of NASDAQ:VRNA opened at $106.91 on Friday. The firm has a market cap of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a 12 month low of $31.09 and a 12 month high of $106.93. The company’s fifty day simple moving average is $106.51 and its 200 day simple moving average is $94.01. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.14. The firm had revenue of $103.14 million during the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. As a group, research analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRNA has been the subject of a number of analyst reports. Wolfe Research cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Truist Financial lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. TD Cowen downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, Roth Capital lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Verona Pharma PLC American Depositary Share presently has a consensus rating of “Hold” and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.